… role of IFN-β in COVID-19 and other diseases caused by emerging viruses, would help build
knowledge on the safety of different therapeutic options for people with MS in the context of …

… Other points considered were the higher chance of atypical and critical illness in patients
with COVID-19 receiving ICIs and the lack of previous skin toxicity in both patients who were on …

… and, therefore, updates to treatment options presented in this article will be necessary. Here,
we explore the outcomes of cancer immunotherapy, such as immune checkpoint inhibitors (…

… option in the case of COVID-19. This article discusses the application of convalescent plasma
as an immunotherapy in … diseases, focusing on the recent COVID-19 outbreak in China. …

… are an option in the inflammatory phase. B: Affected alveolus during both phases of COVID-19.
Left: … host stage; * potential target of immunotherapies with antiviral potential; $ leukocyte …

… remedy and a promising way to manage COVID-19. These approaches are based on …
immunotherapy and immunomodulation approaches in managing and treating COVID-19 patients …

… on 105 patients with cancer who also had a COVID-19 infection. The … illness among patients
who received immunotherapy or had … -19 era due to the multiple treatment options, including …

… disease 2019 (COVID-19), can persist for a long time. This contributes to a long disease …
gamma to five COVID-19 patients with impaired immune systems. These patients were critically …

… COVID-19 [3-7]. Despite the extensive efforts made to develop effective vaccines, drugs,
immunotherapeutics, … Several of the available options have shown promising results in in vitro …

… cancer patients deserving immunotherapy in the current context of the COVID-19 pandemic
… status compared with that of cancer patients undergoing chemotherapy or targeted agents. …